VGI PARTNERS PTY Ltd boosted its stake in shares of CME Group Inc. (NASDAQ:CME) by 6.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 669,068 shares of the company’s stock after buying an additional 38,578 shares during the period. CME Group makes up approximately 18.2% of VGI PARTNERS PTY Ltd’s holdings, making the stock its largest position. VGI PARTNERS PTY Ltd’s holdings in CME Group were worth $69,931,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CME. Bronfman E.L. Rothschild L.P. boosted its stake in shares of CME Group by 4.0% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 1,155 shares of the company’s stock valued at $121,000 after buying an additional 44 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of CME Group by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,621 shares of the company’s stock valued at $157,000 after buying an additional 1,325 shares during the last quarter. Advisors Preferred LLC bought a new stake in shares of CME Group during the third quarter valued at about $180,000. Warren Averett Asset Management LLC bought a new stake in shares of CME Group during the third quarter valued at about $211,000. Finally, Parametrica Management Ltd bought a new stake in shares of CME Group during the second quarter valued at about $212,000. 79.41% of the stock is owned by hedge funds and other institutional investors.
CME Group Inc. (NASDAQ:CME) opened at 117.25 on Thursday. The company’s 50-day moving average price is $118.30 and its 200-day moving average price is $108.56. The stock has a market capitalization of $39.79 billion, a PE ratio of 27.33 and a beta of 0.83. CME Group Inc. has a one year low of $81.87 and a one year high of $124.01.
CME Group (NASDAQ:CME) last released its quarterly earnings results on Thursday, October 27th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.01. CME Group had a return on equity of 6.90% and a net margin of 41.54%. The company earned $842 million during the quarter, compared to analysts’ expectations of $855.94 million. During the same period in the previous year, the firm posted $1.02 earnings per share. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. Equities research analysts predict that CME Group Inc. will post $4.49 EPS for the current year.
The business also recently declared a dividend, which was paid on Friday, January 13th. Stockholders of record on Wednesday, December 28th were issued a $3.25 dividend. This is a boost from CME Group’s previous dividend of $2.90. The ex-dividend date of this dividend was Friday, December 23rd. CME Group’s payout ratio is 55.94%.
A number of research firms have recently weighed in on CME. Royal Bank Of Canada lowered their price target on CME Group from $97.00 to $92.00 and set an “underperform” rating for the company in a report on Friday, October 28th. Jefferies Group reiterated a “buy” rating and set a $118.00 price target on shares of CME Group in a report on Thursday, October 13th. JPMorgan Chase & Co. cut CME Group from an “overweight” rating to a “neutral” rating and set a $116.00 price target for the company. in a report on Monday, November 14th. They noted that the move was a valuation call. Zacks Investment Research upgraded CME Group from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Tuesday, January 10th. Finally, Deutsche Bank AG increased their price target on CME Group from $115.00 to $116.00 and gave the stock a “buy” rating in a report on Wednesday, October 5th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $103.96.
In other news, CEO Terrence A. Duffy sold 27,550 shares of the business’s stock in a transaction on Thursday, December 8th. The stock was sold at an average price of $120.44, for a total value of $3,318,122.00. Following the completion of the transaction, the chief executive officer now directly owns 137,914 shares of the company’s stock, valued at $16,610,362.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO John W. Pietrowicz sold 7,500 shares of the business’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $116.77, for a total value of $875,775.00. Following the completion of the transaction, the chief financial officer now directly owns 39,669 shares of the company’s stock, valued at $4,632,149.13. The disclosure for this sale can be found here. 0.61% of the stock is owned by insiders.
CME Group Company Profile
CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME).